Study finds that weight loss from Mounjaro not only ends, but other health benefits also reverse.
A recent study has revealed that when people stop using the weight-loss medication Mounjaro, not only do they regain weight, but other improvements in their cardiovascular health also begin to decline. The study, which looked at data from over 300 participants who had lost at least 10% of their body weight while on the medication, found that those who stopped taking tirzepatide β the active ingredient in Mounjaro β experienced a reversal in measures such as waist circumference, "bad" cholesterol levels, blood pressure, and blood glucose levels.
Experts say this is not surprising, given that excess weight is a well-known driver of high blood pressure and impaired glucose control. The study's findings suggest that when people regain weight after stopping the medication, their cardiovascular risk factors tend to increase accordingly. This highlights the importance of sustained weight management through lifestyle changes and obesity treatment medications in order to maintain health benefits.
The researchers also noted that stopping tirzepatide could remove a protective effect against hospitalization for heart failure or death from any cause. The study's lead author emphasized that maintaining long-term weight loss requires continued support, such as regular exercise and healthy eating habits.
A recent study has revealed that when people stop using the weight-loss medication Mounjaro, not only do they regain weight, but other improvements in their cardiovascular health also begin to decline. The study, which looked at data from over 300 participants who had lost at least 10% of their body weight while on the medication, found that those who stopped taking tirzepatide β the active ingredient in Mounjaro β experienced a reversal in measures such as waist circumference, "bad" cholesterol levels, blood pressure, and blood glucose levels.
Experts say this is not surprising, given that excess weight is a well-known driver of high blood pressure and impaired glucose control. The study's findings suggest that when people regain weight after stopping the medication, their cardiovascular risk factors tend to increase accordingly. This highlights the importance of sustained weight management through lifestyle changes and obesity treatment medications in order to maintain health benefits.
The researchers also noted that stopping tirzepatide could remove a protective effect against hospitalization for heart failure or death from any cause. The study's lead author emphasized that maintaining long-term weight loss requires continued support, such as regular exercise and healthy eating habits.